Regeneratepanama

  • ES
  • EN
    • FAQ
    Get Started Today
    Menu
    Book consultation
    1-888-491-5223
    • Regeneration Clinic Treatments

    Multiple System Atrophy

    Our Method

    Our Unique Approach to Multiple System Atrophy

    Multiple system atrophy (MSA) is a sporadic, progressive, adult-onset degenerative disease that presents with a combination of parkinsonism, cerebellar and autonomic dysfunction. Its diagnosis is challenging and delayed diagnosis is common  making early, targeted intervention all the more critical.

     

    Understanding MSA

    Multiple system atrophy (MSA) is a sporadic, progressive, adult-onset, degenerative disease that presents with a combination of parkinsonism, cerebellar and autonomic dysfunction. MSA is a synucleinopathy, characterised by α-synuclein-positive oligodendrocytic glial cytoplasmic inclusions, also known as Papp-Lantos bodies. The diagnosis of this disease is challenging and its delayed diagnosis is common.

    Clinical Variants of MSA

    Clinically, the condition is categorised into MSA-parkinsonian variant (MSA-P) and MSA-cerebellar variant (MSA-C), based on the predominant motor phenotype. MSA-P is associated with striatonigral degeneration pathology and MSA-C with olivopontocerebellar atrophy, although most patients have mixed clinical and pathological features.

    MSC Clinical Trial Findings

    In a phase I/II study, Singer et al. explored the intrathecal administration of mesenchymal stem cells (MSCs) as a therapeutic approach to MSA. Twenty-four patients received treatment with no attributable serious adverse events, and injections were generally well-tolerated. The observed clinical effect was associated with a marked rise in neurotrophic factors in the spinal fluid, documented to be present for at least 4 weeks following MSC administration.

    MSCs as Disease Modifiers

    The neurotrophic factor response was dose-dependent and convincingly seen in the medium- and high-dose tiers. There is increasingly convincing evidence based on preclinical studies and clinical trials that MSCs have an intriguing potential of modifying the disease course of MSA, offering a meaningful pathway toward slowing progression and improving patient outcomes.